Articles On Imugene (ASX:IMU)

It's fair to say that ASX 300 property stock Lifestyle Communities Ltd (ASX: LIC) has not had a great year so far in 2024. As it stood yesterday afternoon, Lifestyle Communities shares were down a painful 53% or so this year. Yep, this prop...

The S&P/ASX 200 Index (ASX: XJO) is out of form on Tuesday and dropping into the red. In afternoon trade, the benchmark index is down 0.4% to 8,132.7 points. Four ASX shares that are not letting that hold them back are listed below. He...

Clinical-stage immuno-oncology company Imugene is celebrating more than two years’ “complete response” for one of its bile tract cancer trial therapy subjects in its CF33 MAST VAXINIA study.

ASX exchange-traded funds (ETFs) have surged in popularity over the past few years, especially among younger investors. They offer a quick and easy way to achieve instant diversification by purchasing a basket of ASX shares or internati...

This article was originally published on Fool.com. All figures quoted in US dollars unless otherwise stated. Looking at Wall Street analysts' price targets can be a worthy exercise, because it may identify some stocks with huge upsides you...

Highlights In the Phase 1 MAST trial for VAXINIA, a bile tract cancer patient has maintained a complete response for over two years. The Bile Tract Cancer Expansion phase has cleared its first cohort with no dose limiting toxicities, a...

Those who own ASX shares face an existential trilemma: how much cash to hold, how to finance new investments, and when to sell existing ones. Cash has to come from somewhere to purchase new assets. Keeping cash on the sidelines is one w...

Imugene Ltd (ASX: IMU) shares are having a strong start to the session on Tuesday. At the time of writing, the ASX 300 stock is up 11% to 4.9 cents. Why is this ASX 300 stock jumping? The catalyst for today's strong gain has been the releas...

Imugene (ASX:IMU), a clinical-stage immuno-oncology company, has reported a significant achievement in its Phase 1 MAST (Metastatic Advanced Solid Tumours) trial. The company announced that a patient with bile tract cancer has now maintaine...

Shares in the embattled Star Entertainment Group Ltd (ASX: SGR) extended losses on Monday and finished the session nearly 7% in the red. The stock now fetches 21 cents apiece, bringing losses to more than 20% over the past week and nearl...

The Woolworths Group Ltd (ASX: WOW) share price has dropped 25% since June 2023 and close to 20% from 28 August 2024. On Friday, it dropped to a 52-week low of $29.79. As the chart above shows, Woolworths' supermarket business has de...

Are you looking to supercharge your portfolio with some big returns? If you are, it could pay to listen to what brokers are saying about the ASX shares listed below. They have been named as buys and tipped to rise strongly from current leve...

The S&P/ASX 200 Index (ASX: XJO) is wrapping up the trading week on a decidedly sour note this Friday. At the time of writing, the ASX 200 has dropped by a painful 0.99% and is back below 8,100 points. But let's talk about what's going...

  ASX slips  amid earnings updates and company meetings AGL drops over 6pc after downgrade, while Origin Energy rises Talga surges after Sweden approves graphite mine   The ASX slipped by 0.22% after being dragged by a flurry of company...

The ASX200 has been down a third of a percent (0.32%) at 8,154 points. Consumer Staples continue to be the worst performing sector, down 1.7%, with well-known plays Woolworths (ASX:WOW), Bega Cheese (ASX:BGA) and Elders (ASX:ELD) all dra...

The AGL Energy Limited (ASX: AGL) share price fell 6.9% to an intraday low of $10.38 on Thursday. The ASX utilities stock has recovered a little to be trading at $10.49 at the time of writing, down 5.96%. The energy provider has not...

Two S&P/ASX All Ordinaries Index (ASX: XJO) ASX healthcare shares are making big moves today following the release of their quarterly performance updates. One is racing ahead of the 0.2% losses posted by the All Ordinaries Index (ASX: X...

The S&P/ASX 200 Index (ASX: XJO) is having another relatively poor session on Thursday. In afternoon trade, the benchmark index is down 0.2% to 8,164.1 points. Four ASX shares that are falling more than most today are listed below. Her...

The stock market is one of the best places to invest for long-term returns. That's why I'm not afraid of an S&P/ASX 200 Index (ASX: XJO) sell-off in 2024, 2025, or any other year. There are different buyers and sellers each day who...

Woolworths Group Ltd (ASX: WOW) shares had a difficult time on Wednesday and were sold off by investors. The retail giant's shares ended the session 6% lower at $30.81. This leaves them trading within touching distance of a 52-week low. Why...

Healthcare stocks are doing relatively well globally in 2024
 The sector could see more recovery as Fed cuts rates
 How ASX biotechs performed in the month of September   The S&P 500 Health Care Index, a key world benchmark for health...

Highlights Orphan Drug Designation (ODD) has been secured from the US FDA for VAXINIA (CF33-hNIS). Benefits of ODD include grant funding, tax credits, fee waivers, and seven years of market exclusivity following FDA approval. The MAST...

Imugene has landed a prized FDA orphan drug approval for its bile tract cancer therapy following positive results from its recent metastatic advanced solid tumour trials to treat the rare and insidious disease.

Appen Ltd (ASX: APX) shares have been on a meteoric rise, surging 260% higher in just seven weeks. Shares in the language technology data company were swapping hands at 43 cents per share on July 29, their lowest point in months. At...

The Appen Ltd (ASX: APX) share price is off to the races today. Shares in the All Ordinaries Index (ASX: XAO) AI stock closed yesterday trading for $1.29. In afternoon trade on Thursday, shares are swapping hands for $1.52 apiece, up 18...

DroneShield Ltd (ASX: DRO) shares are rebounding on Wednesday morning after a 7% decline yesterday. In morning trade, the counterdrone technology company's shares are up 7% to $1.33. This compares favourably to the 0.1% gain by the benchmar...

DroneShield Ltd (ASX: DRO) shares have been a top performer this year, soaring 236% into the green to fetch $1.24 at Tuesday's close. The giant leap in market value is underpinned by equally strong growth in DroneShield's underlying busi...

In early afternoon trade, the S&P/ASX 200 Index (ASX: XJO) is back on form and pushing higher. At the time of writing, the benchmark index is up 0.3% to 7,975.3 points. Four ASX shares that are rising more than most today are listed bel...

In afternoon trade, the S&P/ASX 200 Index (ASX: XJO) is on course to record a very disappointing decline. At the time of writing, the benchmark index is down 1.8% to 7,956.8 points. Four ASX shares that are not letting that hold them ba...

S&P/ASX All Ordinaries Index (ASX: XAO) stock Cettire Ltd (ASX: CTT) has gained momentum recently and climbed 18% in the past month of trade. Today, the luxury online retailer posted an announcement advising that its Founder and CEO,...

ASX health stocks down in August and trail the broader market in 2024 CSL up 6,000pc since listing; sector outpaced benchmark 10x since 2006 AI is revolutionising healthcare, boosting diagnosis and treatment   The ASX Healthcare Index (AS...

S&P/ASX All Ords (ASX: XAO) shares essentially moved sideways in August, losing just 0.04%. However, this belies the volatility we saw last month as stocks lurched back and forth on earnings reports. As is typical during earnin...

The first two blood cancer patients in a US-based trial, who had suffered relapses despite having treatment, have now been in remission for up to 120 days after being dosed with Imugene’s azer-cel therapy.

The ASX200 has closed up 0.22% at 8110 after shaking off early losses. Sectors were a hodgepodge with Financials the best performer, up 1.15%, followed closely by Energy 1.1%. Materials was the worst performer, down around 1.1% and Telec...

The Australian sharemarket made notable strides on Monday, approaching its record closing high, thanks to robust performances from major banks and energy stocks, despite pressures from the mining sector. The S&P/ASX 200 Index edged 0.2%...

The ASX ended higher after a slow start Energy stocks leading while telcos and miners lagged Asian stocks mostly declined amid ongoing economic weakness    After a sluggish start, the ASX ended Monday higher by 0.22% as September trading...

In the first session of the week, the Australian sharemarket is experiencing a steady performance, with major banks and miners exerting opposing influences on the S&P/ASX 200 index. As trading enters its final hours, the index remains r...

In the first trading session of the week, the Australian sharemarket is experiencing a downward trend, primarily influenced by movements in the mining and communications sectors.  As of midday, the S&P/ASX 200 Index (ASX: XJO) is down...

With so many shares to choose from on the Australian share market, it can be difficult to decide which ones to buy. The good news is that brokers across the country are doing a lot of the hard work for you. Three top ASX shares that leading...

The ASX200 has been up down 0.12% at 8,082 points, even on the back of Wall Street chalking up solid gains on Friday. Australian second quarter GDP growth figures are out this Wednesday and the consensus forecast is a further slowing in...

  Imugene (ASX:IMU) announced promising results from its Phase 1b clinical trial with azer-cel, in patients with relapsed/refractory diffuse large B cell lymphoma. All enrolled patients had cancer that had returned following autologous CAR...

In afternoon trade, the S&P/ASX 200 Index (ASX: XJO) is on course to start the week with a decline. At the time of writing, the benchmark index is down 0.2% to 8,074.4 points. Four ASX shares that are not letting that hold them back ar...

The DroneShield Ltd (ASX: DRO) share price is leaping higher today despite the broader stock market selling action. Shares in the All Ordinaries Index (ASX: XAO) drone defence company closed on Friday trading for $1.33. In early afterno...

Imugene Ltd (ASX: IMU) shares are starting the week with a bang. In morning trade, the ASX All Ords stock is up 30% to 8.1 cents. Why is this ASX All Ords stock rocketing? Investors have been fighting to get hold of the clinical stage immun...

Imugene’s stock surges on promising Phase 1b results Emyria’s MDMA therapy for PTSD shows quality of life improvements Both companies are expanding their programs and advancing towards further trials   Imugene reports advances in Azer-Cel...

Highlights Ten patients were enrolled in the Phase 1b trial of azer-cel, divided into two cohorts: Cohort A (azer-cel and lymphodepletion) and Cohort B (azer-cel, lymphodepletion, and IL-2). Three patients (two from Cohort B, one from...

Good morning, and welcome to Stockhead’s Top 10 at shortly-before-11-ish, which is meant to highlight the best (and sometimes worst) performing ASX stocks in morning trade using live data, to provide a short, sharp update to help frame the...

Imugene (ASX: IMU) has announced positive results from a Phase 1b clinical trial using lead candidate azer-cel on patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL). Ten enrolled patients had previously undergone up...

Imugene (ASX:IMU) has announced 3 patients in its latest blood cancer treatment trial using azer-cel have responded well with one showing a complete response for over 100 days. A ‘complete response’ in this case is a complete disappeara...

Cettire Ltd (ASX: CTT) shares were hammered last week. Investors were hitting the sell button after the ASX tech share released its disappointing full year results. The online luxury products retailer reported an 81% increase in gross reven...